OBJECTIVE: To evaluate the individual components of a cardiac multimarker panel in the detection of acute myocardial infarction (AMI) in patients with chest pain across a spectrum of renal dysfunction. METHODS: A total of 817 consecutive patients evaluated for a possible AMI in the emergency department (ED) enrolled in a prospective study of cardiac biomarkers assessed using a point-of-care device with myoglobin (MYO), cardiac troponin I (cTnI), and creatine kinase myocardial band (CK-MB), recorded at 0, 1.5, 3, and 9 hours. This study did not exclude patients on the basis of renal dysfunction. Baseline renal function was available in 808 patients. Patients were stratified by corrected creatinine clearance (CorrCrCl) into quartiles, and those on dialysis (n = 51) were considered as a fifth comparison group. Those patients with advanced renal dysfunction (CorrCrCl < 47/mL/min/72 kg) or on dialysis had higher rates of diabetes, hypertension, and prior coronary disease. Agreement for the diagnosis of AMI was required of two independent cardiologists using criteria based on history, electrocardiogram, and central laboratory assessment of serial cardiac markers. RESULTS: More than 99% of all patients were admitted to a chest pain observation unit or the hospital. Mean MYO levels were elevated in the presence of renal dysfunction in those with and without myocardial infarction. Both MYO and CK-MB were correlated with CorrCrCl, (r = -0.36, p < 0.01, and r = -0.10, p = 0.01, respectively), while cTnI was not (r = -0.10, p = 0.12). Using multiple receiver operating characteristic curve testing, cTnI was found to be the most consistent marker across all strata of renal dysfunction, including end-stage renal disease on dialysis. The authors did not find a trend for false-positive cTnI and renal dysfunction. CONCLUSIONS: A point-of-care, rapid cardiac biomarker strategy utilizing cTnI is applicable and superior to MYO or CK-MB in the evaluation of chest pain in patients with renal dysfunction.
OBJECTIVE: To evaluate the individual components of a cardiac multimarker panel in the detection of acute myocardial infarction (AMI) in patients with chest pain across a spectrum of renal dysfunction. METHODS: A total of 817 consecutive patients evaluated for a possible AMI in the emergency department (ED) enrolled in a prospective study of cardiac biomarkers assessed using a point-of-care device with myoglobin (MYO), cardiac troponin I (cTnI), and creatine kinase myocardial band (CK-MB), recorded at 0, 1.5, 3, and 9 hours. This study did not exclude patients on the basis of renal dysfunction. Baseline renal function was available in 808 patients. Patients were stratified by corrected creatinine clearance (CorrCrCl) into quartiles, and those on dialysis (n = 51) were considered as a fifth comparison group. Those patients with advanced renal dysfunction (CorrCrCl < 47/mL/min/72 kg) or on dialysis had higher rates of diabetes, hypertension, and prior coronary disease. Agreement for the diagnosis of AMI was required of two independent cardiologists using criteria based on history, electrocardiogram, and central laboratory assessment of serial cardiac markers. RESULTS: More than 99% of all patients were admitted to a chest pain observation unit or the hospital. Mean MYO levels were elevated in the presence of renal dysfunction in those with and without myocardial infarction. Both MYO and CK-MB were correlated with CorrCrCl, (r = -0.36, p < 0.01, and r = -0.10, p = 0.01, respectively), while cTnI was not (r = -0.10, p = 0.12). Using multiple receiver operating characteristic curve testing, cTnI was found to be the most consistent marker across all strata of renal dysfunction, including end-stage renal disease on dialysis. The authors did not find a trend for false-positive cTnI and renal dysfunction. CONCLUSIONS: A point-of-care, rapid cardiac biomarker strategy utilizing cTnI is applicable and superior to MYO or CK-MB in the evaluation of chest pain in patients with renal dysfunction.
Authors: Gürsel Yildiz; Mansur Kayataş; Ferhan Candan; Mehmet Birhan Yilmaz; Ali Zorlu; Savaş Sarikaya Journal: Cardiorenal Med Date: 2013-06-25 Impact factor: 2.041
Authors: Michael Walsh; Chew-Yin Wang; Gracie S Y Ong; Alvin S B Tan; Marzida Mansor; Ina I Shariffuddin; Noorjahan H M Hashim; Hou Yee Lai; A Wahab Undok; Ushananthini N Kolandaivel; Vasanthan Vajiravelu; Amit X Garg; Meaghan Cuerden; Gordon Guyatt; Lehana Thabane; John Mooney; Vincent Lee; Clara Chow; Phillip J Devereaux Journal: J Am Soc Nephrol Date: 2015-02-23 Impact factor: 10.121
Authors: Martina Montagnana; Giuseppe Lippi; Nicola Tessitore; Gian Luca Salvagno; Giovanni Targher; Matteo Gelati; Antonio Lupo; Gian Cesare Guidi Journal: J Clin Lab Anal Date: 2008 Impact factor: 2.352
Authors: Mohammad Javad Hajipour; Mehdi Mehrani; Seyed Hesameddin Abbasi; Ahmad Amin; Seyed Ebrahim Kassaian; Jessica C Garbern; Giulio Caracciolo; Steven Zanganeh; Mitra Chitsazan; Haniyeh Aghaverdi; Seyed Mehdi Kamali Shahri; Aliakbar Ashkarran; Mohammad Raoufi; Holly Bauser-Heaton; Jianyi Zhang; Jochen D Muehlschlegel; Anna Moore; Richard T Lee; Joseph C Wu; Vahid Serpooshan; Morteza Mahmoudi Journal: Chem Rev Date: 2019-09-06 Impact factor: 60.622